GLP-1 Agonists and Neurological Adverse Events in FAERS
Chen H, Liu S, Gao S, Shi H, Yan Y, Xu Y, Fang J, Wang W, Chen H, Liu Z. Pharmacovigilance analysis of neurological adverse events associated with GLP-1 receptor agonists based on the FDA Adverse Event Reporting System. Sci Rep. 2025 May 24;15(1):18063. doi: 10.1038/s41598-025-01206-9. PMID: 40413246; PMCID: PMC12103604. This research utilizes data from […]
MAHA Agenda Excludes GLP-1 Coverage Expansion
PharmaVoice article discusses the Trump administration’s decision not to expand Medicare and Medicaid coverage for GLP-1 obesity drugs, despite their increasing use and the potential for significant market growth for companies like Eli Lilly and Novo Nordisk. Although a Biden-era proposal to expand coverage was rejected due to concerns about the high cost to the federal government, […]
Regeneron pens $2B pact for Hansoh’s potential obesity rival to Lilly’s Zepbound
Regeneron is paying Hansoh Pharma $80 million upfront for a phase 3-stage GLP-1/GIP receptor agonist the companies believe can hold its own against Eli Lilly’s Zepbound.
Could Viking Therapeutics Become the Next Eli Lilly?
The obesity treatment market is booming, with groundbreaking drugs like Eli Lilly‘s (NYSE: LLY) Zepbound delivering transformative patient results and powering its stock to a spectacular 400% return in the past five years. Amid this estimated $100 billion opportunity, much smaller upstart Viking Therapeutics (NASDAQ: VKTX) has emerged with a promising clinical pipeline, aiming to […]
Mainland Chinese market for weight loss and diabetes drugs to soon be more crowded: report
2025.06.02 10:36 Novo Nordisk’s semaglutide product. Photo: Handout Competition in the mainland Chinese market for diabetes and weight loss drugs is set to intensify as more than 60 late-stage drug candidates are undergoing clinical trials, according to a recent report. Up to 20 biosimilar or generic copies will vie for market share and add pricing […]
“I’m Thin, And I’m Yellow”: Doctors Sound Alarm On Concerning New Ozempic Side Effect
The “miracle weight-loss drug” Ozempic, once hailed as a shortcut to shedding pounds without the hard work, is now at the center of an alarming health scare. Dozens of Australians taking semaglutide-based medications—Ozempic, Wegovy, and Mounjaro—have come forward with reports of dr*g-induced hepatitis, a form of liver inflammation caused by medications or toxins. Some patients […]